
DocGo (DCGO) Stock Forecast & Price Target
DocGo (DCGO) Analyst Ratings
Bulls say
DocGo Inc. demonstrates a positive financial outlook, with a reported EBITDA of $830,000 and a 20% margin, indicating strong operational efficiency as the company scales its business. The significant year-over-year growth in patient volumes, including an 113% increase in home visits and a 50% rise in telehealth and lab orders, highlights the demand for its mobile health services and positions the company for continued revenue expansion. Furthermore, the company has raised its revenue and adjusted EBITDA guidance for 2026, reflecting improved performance in its transportation services segment, which is anticipated to contribute to sustained growth and profitability moving forward.
Bears say
DocGo Inc. reported a decline in mobile revenue of 3% year-over-year and 8% quarter-over-quarter for 4Q25, excluding acquisitions and one-time factors. The company faces significant challenges in achieving its adjusted EBITDA guidance, necessitating a reduction of approximately $20 to $22 million in non-GAAP operating expenses amid stagnating organic growth in its core Mobile Health Services segment. Notably, while there was a reported 47% growth in the non-migrant Mobile Health business, the exclusion of SteadyMD's $6.1 million contribution reveals an underlying decline in organic revenue, indicating that the company struggles to scale its fundamental operations effectively.
This aggregate rating is based on analysts' research of DocGo and is not a guaranteed prediction by Public.com or investment advice.
DocGo (DCGO) Analyst Forecast & Price Prediction
Start investing in DocGo (DCGO)
Order type
Buy in
Order amount
Est. shares
0 shares